Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Alzheimer's Research & Therapy
Published in: Alzheimer's Research & Therapy 1/2017

Open Access 01-12-2017 | Research

Validating the role of the Australian National University Alzheimer’s Disease Risk Index (ANU-ADRI) and a genetic risk score in progression to cognitive impairment in a population-based cohort of older adults followed for 12 years

Authors: Shea J. Andrews, Ranmalee Eramudugolla, Jorge I. Velez, Nicolas Cherbuin, Simon Easteal, Kaarin J. Anstey

Published in: Alzheimer's Research & Therapy | Issue 1/2017

Login to get access

Abstract

Background

The number of people living with dementia is expected to exceed 130 million by 2050, which will have serious personal, social and economic implications. Employing successful intervention and treatment strategies focused on disease prevention is currently the only available approach that can have an impact on the projected rates of dementia, with risk assessment being a key component of population-based risk reduction for identification of at-risk individuals. We evaluated a risk index comprising lifestyle, medical and demographic factors (the Australian National University Alzheimer’s Disease Risk Index [ANU-ADRI]), as well as a genetic risk score (GRS), for assessment of the risk of progression to mild cognitive impairment (MCI).

Methods

The ANU-ADRI was computed for the baseline assessment of 2078 participants in the Personality and Total Health (PATH) Through Life project. GRSs were constructed on the basis of 25 single-nucleotide polymorphisms previously associated with Alzheimer’s disease (AD). Participants were assessed for clinically diagnosed MCI and dementia as well as psychometric test-based MCI (MCI-TB) at 12 years of follow-up. Multi-state models were used to estimate the odds of transitioning from cognitively normal (CN) to MCI, dementia and MCI-TB over 12 years according to baseline ANU-ADRI and GRS.

Results

A higher ANU-ADRI score was associated with increased risk of progressing from CN to both MCI and MCI-TB (HR 1.07 [95% CI 1.04–1.11]; 1.07 [1.04–1.09]). The GRS was associated with transitions from CN to dementia (HR 4.19 [95% CI 1.72–10.20), but not to MCI or MCI-TB (HR 1.05 [95% CI 0.86–1.29]; 1.03 [0.87–1.21]). Limitations of our study include that the ethnicity of participants in the PATH project is predominately Caucasian, potentially limiting the generalisability of the results of this study to people of other ethnicities. Biomarkers of AD were not available to define MCI attributable to AD. Not all the predictive variables for the ANU-ADRI were available in the PATH project.

Conclusions

In the general population, the ANU-ADRI, comprising lifestyle, medical and demographic factors, is associated with the risk of progression from CN to MCI, whereas a GRS comprising the main AD risk genes was not associated with this risk. The ANU-ADRI may be used for population-level risk assessment and screening.
Appendix
Available only for authorised users
Literature
1.
Stephan BCM, Kurth T, Matthews FE, Brayne C, Dufouil C. Dementia risk prediction in the population: are screening models accurate? Nat Rev Neurol. 2010;6:318–26.CrossRefPubMed
2.
Tang EYH, Harrison SL, Errington L, Gordon MF, Visser PJ, Novak G, et al. Current developments in dementia risk prediction modelling: an updated systematic review. PLoS One. 2015;10:e0136181.CrossRefPubMedPubMedCentral
3.
Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9:63–75.e2.CrossRefPubMed
4.
Anstey KJ, Eramudugolla R, Dixon RA. Contributions of a risk assessment approach to the prevention of Alzheimer’s disease and dementia. J Alzheimers Dis. 2014;42 Suppl 4:S463–73.PubMed
5.
Pankratz VS, Roberts RO, Mielke MM, Knopman DS, Jack CR, Geda YE, et al. Predicting the risk of mild cognitive impairment in the Mayo Clinic Study of Aging. Neurology. 2015;84:1433–42.CrossRefPubMedPubMedCentral
6.
Karch CM, Goate AM. Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry. 2015;77:43–51.CrossRefPubMed
7.
Verhaaren BFJ, Vernooij MW, Koudstaal PJ, Uitterlinden AG, van Duijn CM, Hofman A, et al. Alzheimer’s disease genes and cognition in the nondemented general population. Biol Psychiatry. 2013;73:429–34.CrossRefPubMed
8.
Escott-Price V, Sims R, Bannister C, Harold D, Vronskaya M, Majounie E, et al. Common polygenic variation enhances risk prediction for Alzheimer’s disease. Brain. 2015;138:3673–84.CrossRefPubMedPubMedCentral
9.
Adams HHH, de Bruijn RFAG, Hofman A, Uitterlinden AG, van Duijn CM, Vernooij MW, et al. Genetic risk of neurodegenerative diseases is associated with mild cognitive impairment and conversion to dementia. Alzheimers Dement. 2015;11:1277–85.CrossRefPubMed
10.
Carrasquillo MM, Crook JE, Pedraza O, Thomas CS, Pankratz VS, Allen M, et al. Late-onset Alzheimer’s risk variants in memory decline, incident mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging. 2015;36:60–7.CrossRefPubMed
11.
Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303:1832–40.CrossRefPubMedPubMedCentral
12.
Rodríguez-Rodríguez E, Sánchez-Juan P, Vázquez-Higuera JL, Mateo I, Pozueta A, Berciano J, et al. Genetic risk score predicting accelerated progression from mild cognitive impairment to Alzheimer’s disease. J Neural Transm (Vienna). 2013;120:807–12.CrossRef
13.
Lacour A, Espinosa A, Louwersheimer E, Heilmann S, Hernández I, Wolfsgruber S, et al. Genome-wide significant risk factors for Alzheimer’s disease: role in progression to dementia due to Alzheimer’s disease among subjects with mild cognitive impairment. Mol Psychiatry. 2017;22:153–60.CrossRefPubMed
14.
Anstey KJ, Cherbuin N, Herath PM. Development of a new method for assessing global risk of Alzheimer’s disease for use in population health approaches to prevention. Prev Sci. 2013;14:411–21.CrossRefPubMedPubMedCentral
15.
Anstey KJ, Cherbuin N, Herath PM, Qiu C, Kuller LH, López OL, et al. A self-report risk index to predict occurrence of dementia in three independent cohorts of older adults: the ANU-ADRI. PLoS One. 2014;9:e86141.CrossRefPubMedPubMedCentral
16.
Anstey KJ, Christensen H, Butterworth P, Easteal S, Mackinnon A, Jacomb T, et al. Cohort profile: the PATH through life project. Int J Epidemiol. 2012;41:951–60.CrossRefPubMed
17.
National Health and Medical Research Council (NHMRC). Australian alcohol guidelines: health risks and benefits. Canberra: NHMRC; 2001.
18.
Martin A, Rief W, Klaiberg A, Braehler E. Validity of the Brief Patient Health Questionnaire Mood Scale (PHQ-9) in the general population. Gen Hosp Psychiatry. 2006;28:71–7.CrossRefPubMed
19.
Bielak AAM, Cherbuin N, Bunce D, Anstey KJ. Preserved differentiation between physical activity and cognitive performance across young, middle, and older adulthood over 8 years. J Gerontol B Psychol Sci Soc Sci. 2014;69:523–32.CrossRefPubMed
20.
Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet. 2011;43:436–41.
21.
Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet. 2011;43:429–35.
22.
Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet. 2009;41:1088–93.
23.
Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet. 2009;41:1094–9.
24.
Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet. 2013;45:1452–8.CrossRefPubMedPubMedCentral
25.
Andrews SJ, Das D, Cherbuin N, Anstey KJ, Easteal S. Association of genetic risk factors with cognitive decline: the PATH through life project. Neurobiol Aging. 2016;41:150–8.CrossRefPubMed
26.
Andrews SJ, Das D, Anstey KJ, Easteal S. Late onset Alzheimer’s disease risk variants in cognitive decline: the PATH Through Life Study. doi:10.​3233/​JAD-160774.
27.
Jorm AF, Mather KA, Butterworth P, Anstey KJ, Christensen H, Easteal S. APOE genotype and cognitive functioning in a large age-stratified population sample. Neuropsychology. 2007;21:1–8.
28.
29.
Anstey KJ, Cherbuin N, Christensen H, Burns R, Reglade-Meslin C, Salim A, et al. Follow-up of mild cognitive impairment and related disorders over four years in adults in their sixties: the PATH Through Life Study. Dement Geriatr Cogn Disord. 2008;26:226–33.CrossRefPubMedPubMedCentral
30.
Anstey KJ, Cherbuin N, Eramudugolla R, Sargent-Cox K, Easteal S, Kumar R, et al. Characterizing mild cognitive disorders in the young-old over 8 years: prevalence, estimated incidence, stability of diagnosis, and impact on IADLs. Alzheimers Dement. 2013;9:640–8.CrossRefPubMed
31.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.CrossRefPubMed
32.
Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test. San Antonio: Psychological Corporation; 1987.
33.
Smith A. Symbol Digit Modalities Test: manual. Los Angeles: Western Psychological Corporation; 2002.
34.
Tiffin J. Purdue Pegboard examiner manual. Revth ed. Chicago: Science Research Associates; 1968.
35.
Anstey KJ, Dear K, Christensen H, Jorm AF. Biomarkers, health, lifestyle, and demographic variables as correlates of reaction time performance in early, middle, and late adulthood. Q J Exp Psychol A. 2005;58:5–21.CrossRefPubMed
36.
Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412–4.CrossRefPubMed
37.
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303–8.CrossRefPubMed
38.
Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256:240–6.CrossRefPubMed
39.
American Psychiatric Association. Diagnostic criteria for dementia of the Alzheimer’s type. In: Diagnostic and statistical manual of mental disorders (DSM-IV). 4th ed. Washington, DC: American Psychiatric Press; 1994. p. 143–7.
40.
Dixon RA, DeCarlo CA, MacDonald SWS, Vergote D, Jhamandas J, Westaway D. APOE and COMT polymorphisms are complementary biomarkers of status, stability, and transitions in normal aging and early mild cognitive impairment. Front Aging Neurosci. 2014;6:236.CrossRefPubMedPubMedCentral
41.
Wechsler D. A standardized memory scale for clinical use. J Psychol. 1945;19:87–95.CrossRef
42.
Baddeley A, Emslie H, Nimmo-Smith I. The Spot-the-Word test: a robust estimate of verbal intelligence based on lexical decision. Br J Clin Psychol. 1993;32:55–65.CrossRefPubMed
43.
Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Graph Stat. 1996;5:299–314.
44.
Stekhoven DJ, Bühlmann P. MissForest—non-parametric missing value imputation for mixed-type data. Bioinformatics. 2012;28:112–8.CrossRefPubMed
45.
Waljee AK, Mukherjee A, Singal AG, Zhang Y, Warren J, Balis U, et al. Comparison of imputation methods for missing laboratory data in medicine. BMJ Open. 2013;3:e002847.CrossRefPubMedPubMedCentral
46.
Jackson C. Multi-state models for panel data: the msm package for R. J Stat Soft. 2011;38(8):1–29.
47.
Roberts RO, Knopman DS, Mielke MM, Cha RH, Pankratz VS, Christianson TJH, et al. Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal. Neurology. 2014;82:317–25.CrossRefPubMedPubMedCentral
48.
49.
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270–9.CrossRefPubMedPubMedCentral
50.
Kawas CH, Kim RC, Sonnen JA, Bullain SS, Trieu T, Corrada MM. Multiple pathologies are common and related to dementia in the oldest-old: The 90+ Study. Neurology. 2015;85:535–42.CrossRefPubMedPubMedCentral
Metadata
Title
Validating the role of the Australian National University Alzheimer’s Disease Risk Index (ANU-ADRI) and a genetic risk score in progression to cognitive impairment in a population-based cohort of older adults followed for 12 years
Authors
Shea J. Andrews
Ranmalee Eramudugolla
Jorge I. Velez
Nicolas Cherbuin
Simon Easteal
Kaarin J. Anstey
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Alzheimer's Research & Therapy / Issue 1/2017
Electronic ISSN: 1758-9193
DOI
https://doi.org/10.1186/s13195-017-0240-3

Other articles of this Issue 1/2017

Alzheimer's Research & Therapy 1/2017 Go to the issue

Erratum

Erratum to: The societal costs of dementia in Sweden 2012 – relevance and methodological challenges in valuing informal care

Review

PKR involvement in Alzheimer’s disease

Review

Gene suppression approaches to neurodegeneration

Research

Memory is preserved in older adults taking AT1 receptor blockers

Research

Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients

Research

Cognitive profile in prodromal dementia with Lewy bodies